Allstate Corp Takes $514,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Allstate Corp purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 7,134 shares of the medical equipment provider’s stock, valued at approximately $514,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HOLX. General Partner Inc. acquired a new position in shares of Hologic during the fourth quarter worth approximately $26,000. Groupama Asset Managment raised its holdings in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

NASDAQ HOLX opened at $61.38 on Wednesday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market cap of $13.77 billion, a PE ratio of 19.36, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The firm’s 50-day simple moving average is $64.90 and its two-hundred day simple moving average is $72.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on HOLX shares. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Stephens reissued an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.